Merus N.V. (MRUS) PT Raised to $84 at BMO Capital

Merus N.V. (MRUS) PT Raised to $85 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the price target on Merus N.V. (NASDAQ: MRUS) to $85.00 (from $65.00) while maintaining a Buy rating.

The analyst comments "Valuation and risks to reaching our price target. Given the recent ASCO update for petosemtamab, we are... More

Merus N.V. (MRUS) PT Raised to $80 at BofA Securities

BofA Securities analyst Tazeen Ahmad raised the price target on Merus N.V. (NASDAQ: MRUS) to $80.00 (from $61.00) while maintaining a Buy rating.

The analyst comments "Merus reported 67% objective response rate (ORR; 1 CR, 15 PR) in 24 evaluable 1L head and neck squamous cell carcinoma (HNSCC)... More

Merus N.V. (MRUS) PT Raised to $90 at Stifel

(Updated - May 28, 2024 10:19 AM EDT)

Stifel analyst Bradley Canino raised the price target on Merus N.V. (NASDAQ: MRUS) to $90.00 (from $65.00) while maintaining a Buy rating.

The analyst commented: "GLNG is trading down 2%-3% this morning after reporting Q1 earnings (BMO) with adjusted EBITDA of ~$64M, which was ~5% below consensus of ~$67M... More

BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $58.00 price target on Merus N.V. (NASDAQ: MRUS).

The analyst comments "MRUS announced updated data from the Phase 1/2 trial evaluating petosemtamab/ pembrolizumab in 1L HNSCC patients, reporting a 67% ORR in 24 patients, including a 75%... More

Merus' (MRUS) Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a March 6, 2024 data cutoff from the ongoing phase 1/2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Jerome Fayette M.D. Ph.D., Centre Léon Bérard, Lyon,... More

Merus N.V. (MRUS) 30-day option implied volatility amid price movement

Merus N.V. (NASDAQ: MRUS) 30-day option implied volatility is at 88; compared to its 52-week range of 56 to 140 amid wide price movement.

Merus N.V. (MRUS) call put ratio 1 call to 2.2 puts as share price up 35%

Merus N.V. (NASDAQ: MRUS) 30-day option implied volatility is at 99; compared to its 52-week range of 56 to 136. Call put ratio 1 call to 2.2 puts as share price up 35%.

TD Cowen Reiterates Buy Rating on Merus N.V. (MRUS)

TD Cowen analyst Tara Bancroft reiterated a Buy rating on Merus N.V. (NASDAQ: MRUS).

The analyst commented, "Peto + pembro's 60% cORR in the ASCO abstract far exceeds the ~20% of pembro mono and the 45-50% of other EGFRis. It's also in-line with more mature... More

BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $58.00 price target on Merus N.V. (NASDAQ: MRUS).

The analyst commented, "ASCO abstracts have been released for MRUS (a Top Pick) including data for petosemtamab, MCLA-145, and MCLA-129. The petosemtamab... More

Merus (MRUS) Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting... More